The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia (AML) and other hematologic cancers.
MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers
- Post author:
- Post published:December 8, 2023
- Post category:uncategorized